Advances in pretransfusion infectious disease testing: Ensuring the safety of transfusion therapy

Clinics in Laboratory Medicine

Volumn 22, Issue 2, 2002, Pages 475-490

  Downes, Katharine A ^a,b,c   Yomtovian, Roslyn ^b,c  

^a AMERICAN RED CROSS   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; PSORALEN DERIVATIVE; RIBOFLAVIN; THIOBUTABARBITAL; TRIBUTYL PHOSPHATE; TRITON X 100; VIRUS DNA; VIRUS RNA;

BACTERIUM CONTAMINATION; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; DNA VIRUS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA VIRUS; SAFETY; SEROLOGY; TORQUE TENO VIRUS; TREPONEMA PALLIDUM; UNITED STATES; BLOODBORNE BACTERIUM; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; METHODOLOGY; PATHOLOGY; STANDARD;

BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES, EMERGING; HUMAN; PATHOLOGY, CLINICAL; SAFETY; HUMANS;

EID: 0035990287     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(01)00007-5     Document Type: Review

References (83)

1. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS)
2. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
3. Safety of the blood supply
4. Nucleic Acid Amplification Testing of Blood Donors for Transfusion Transmitted Infectious Disease. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
5. HIV, HBV and HCV new developments related to transfusion safety
6. Closing the windows on viral transmission by blood transfusion
7. Interactions between science, government, and media on selection and testing of donors
8. Germs, gels, and genomes: A personal recollection of 30 years in blood safety testing
9. Safety of the blood supply in the United States: Opportunities and controversies
10. Oversight and monitoring of blood safety in the United States
11. Creutzfeldt-Jakob disease and blood transfusion
12. Bacterial contamination of blood unit: Emerging concerns and evolving strategies
13. Bacterial contamination of blood components
14. Indeterminate results in blood donor testing: What you don't know can hurt you
15. A new antigen in leukemia sera
16. Prevention of transmission of hepatitis B, hepatitis C and human immunodeficiency virus infections through blood transfusion by anti-HBc testing
17. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome
18. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
19. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period
20. Malignancy: Human T-Cell lymphotropic virus type I and adult T-cell leukaemia/lymphoma
21. Allogeneic bone marrow transplantation-related transmission of human T lymphotropic virus type I (HTLV-I)
22. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in U.S. blood donors
23. Absence of risk factors for false-positive test results in blood donors with a reactive test result in an automated treponemal test (PK-TP) for syphilis
24. Predictive value of past and current screening tests for syphilis in blood donors: Changing from a rapid plasma reagin test to an automated specific treponemal test for screening
25. Residual risk of transfusion transmitted viral infections among seronegative donors: Application of the incidence/window period model
26. Significant closure of the HIV-1 detection window with the TMA HIV-1/HCV assay
27. NAT and viral safety in blood transfusion
28. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C, hepatitis B virus, and HIV-1 in a blood bank setting
29. Detection of hepatitis B seroconversion by highly sensitive assays for surface antigen and HBV DNA
30. Enzymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees
31. HBV viremia preceding HBsAg positivity: Implications for minipool (MP) and individual donation (ID) HBV nucleic acid testing (NAT)
32. Significant closure of the HCV detection window with the TMA HIV-I/HCV assay
33. The risks of transfusion transmitted infection: Direct estimation and mathematical modeling
34. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV
35. Nucleic acid testing for transfusion transmissible agents
36. Automation of nucleic acid extraction for NAT screening of individual blood units
37. Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products
38. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques
39. Transfusion-transmitted bacterial infection
40. Transfusion incidents related to bacterial contamination: Review of the literature and hemovigilance data. For the working group bacterial incidents of French Blood Agency, scientific advice of Bacthem and the French Hemovigilance network
41. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets
42. Skin fragments removed by injection needles
43. Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations
44. Evaluation of an automated culture system for detection bacterial contamination of platelets: An analysis with 15 contaminating organisms
45. Rapid identification of bacterially contaminated platelets using reagent strips: Glucose and pH analysis as markers of bacterial contamination
46. Approaches to the detection of bacterial contamination in cellular blood products
47. Evaluation of BacT/Alert (BTA) microbial detection system testing of platelets
48. Implementation of an automated bacterial culture of platelet products in the blood bank routine
49. A new culture bag set for bacterial detection in leuko reduced platelet transfusion products
50. Application of a universal culturing approach to reduce the risk of bacterial contamination of apheresis platelet units
51. Reduction of platelet transfusion-associated sepsis by short-term bacterial culture
52. Progress in improving the pathogen safety of red cell concentrates
53. The use of Riboflavin for the inactivation of pathogens in blood products
54. Current status of solvent/detergent-treated frozen plasma
55. Completely converting a blood service to the use of safer plasma
56. Clinical illnesses due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma
57. Efficacy of SD treated plasma during liver transplantation
58. Coagulation factor levels in solvent/detergent-treated plasma
59. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
60. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function
61. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats
62. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment
63. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA
64. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light
65. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naîve or primed T lymphocytes in vivo after allogeneic bone marrow transplantation
66. Photochemical inactivation of pathogenic bacteria in human platelet concentrates
67. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates
68. Prion diseases, blood and the immune system: Concerns and reality
69. Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy
70. The dimensions of Creutzfeldt-Jakob disease
71. Pooled plasma derivative and Creutzfeldt-Jakob disease
72. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects
73. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: Integrating science, legal duties and ethical mandates
74. Creutzfeldt-Jakob disease: The problem of recipient notification
75. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives
76. Ultrasensitive detection of pathological prion protein aggregates by dual color scanning for intensely fluorescent targets
77. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein
78. Transmission of BSE by blood transfusion in sheep
79. Old and new tests: Where will it end?
80. The risk of blood-bourne Creutzfeldt-Jakob disease